|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 帕博利珠单抗联合以铂类为基础的化疗治疗非小细胞肺癌合并稳定性脑转移患者的结局:KEYNOTE-021、-189和-407研究的汇总分析显示文摘背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患者和方法对KEYNOTE-021队列G(非鳞癌)、KEYNOTE-189(非鳞癌)和KEYNOTE-407(鳞癌)三项研究晚期NSCLC患者的数据进行汇总分析。患者接受含铂两药化疗和/或35个周期帕博利珠单抗治疗(每3周200 mg)。所有研究均纳入了经治或初治的稳定性脑转移患者(KEYNOTE-189与KEYNOTE-407研究纳入初治脑转移患者)。经治的脑转移患者已处于病情稳定的状态≥2周(KEYNOTE-021队列G患者≥4周),无新发或脑转移病灶扩大的证据且入组前至少3天以上未使用激素。初治的无症状脑转移患者需定期接受脑部影像学检查。结果共纳入1298例患者,其中171例有基线脑转移,1127例无脑转移。两组的中位随访时间(范围)在数据截止时分别为10.9(0.1-35.1)个月和11.0(0.1-34.9)个月。合并脑转移和无脑转移患者的总生存期[0.48(95%CI:0.32-0.70)和0.63(95%CI:0.53-0.75)]和无进展生存期[0.44(95%CI:0.31-0.62)和0.55(95%CI:0.48-0.63)]的风险比(PC/化疗)相似。合并脑转移的患者中,PC组和单用化疗组患者的中位总生存期分别为18.8个月和7.6个月,中位无进展生存期分别为6.9个月和4.1个月。无论是否合并脑转移,PC组患者的客观缓解率都高于单用化疗组,且缓解持续时间有显著延长。合并脑转移的患者中,PC组与单用化疗组的治疗相关不良事件发生率分别为88.2%和82.8%;而无脑转移的患者中,两组治疗相关不良事件的发生率分别为94.5%和90.6%。结论无论是否合并脑转移,与单用化疗相比,帕博利珠单抗联合以铂类为基础的组织学特异性化疗可改善所有PD-L1亚组的临床结局,其中包括PD-L1肿瘤比例评分<1%的患者,并且在晚期NSCLC患者中安全性良好。该方案是晚期NSCLC初治患者的标准方案,并可用于合并稳定性脑转移的患者。 | 周清(翻译校对) Steven F Powell Delvys Rodríguez-Abreu Corey J Langer Ali Tafreshi Luis Paz-Ares Hans-Georg Kopp Jeronimo Rodríguez-Cid Dariusz M Kowalski Ying Cheng Takayasu Kurata Mark M Awad Jinaxin Lin Bin Zhao M Catherine Pietanza Bilal Piperdi Marina C Garassino | 2022 | 中国肺癌杂志2022，25，1： | 6 |
| 2 | Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors显示文摘 | Helena A. Yu Camelia S. Sima James Huang Stephen B. Solomon Andreas Rimner Paul Paik M. Catherine Pietanza Christopher G. Azzoli Naiyer A. Rizvi Lee M. Krug Vincent A. Miller Mark G. Kris Gregory J. Riely | 2013 | Journal of Thoracic Oncology2013，，3： | 2 |
| 3 | 小细胞肺癌的的分子发病机制显示文摘在美国,SCLC(small cell lung cancer,SCLC)占所有确诊肺癌病例的13%。尽管其对放、化疗均较敏感,但SCLC复发迅速,患者的五年生存率仅为5%。这种极差的预后可能要归咎于治疗方式的进展缓慢,因为在过去三十年中,针对SCLC的医疗及护理方案并无明显变化。 | 李红洁 李晓平 Sandra P.DA'NGELO M.Catherine PIETANZA | 2010 | 中国肺癌杂志2010，13，11： | 2 |
| 4 | A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topoteean in relapsed small cell lung cancer显示文摘 | Paik PK Rudin CM Pietanza MC | 2011 | Lung Cancer2011，74，： | 1 |
| 5 | XL647-a multitargeted tyrosine kinase inhibitor: results of a phase H study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib显示文摘 | Pietanza MC Lynch TJ Jr Lara PN Jr etal | 2012 | J Thorac Oncol2012，7，1： | 1 |
| 6 | The molecular pathogenesis of small cell lung cancer显示文摘 | D' Angelo S P Pietanza M C | 2010 | Zhongguo Fei Ai Za Zhi2010，13，11： | 1 |
| 7 | Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas显示文摘 | D'Angel SP Pietanza MC Johnson ML | 2011 | J Clin Oncol2011，29，15： | 1 |
| 8 | The molecular pathogenesis of small cell lung cancer显示文摘 | D'Angelo SP Pietanza MC | 2010 | Cancer Biol Ther2010，10，1： | 1 |
| 9 | Recombination-assisted nitrogen dissociation rates under nonequilibrium conditions 显示文摘 | Colonna G Pietanza L D Capitelle M | 2008 | Journal of Thermophysics and Heat Transfer2008，22，3： | 1 |
| 10 | Incidence of EGFR exon 19 eletions and L8S8R in tumor specimens from men and cigarette smokers with lung adenocarcinomas显示文摘 | DAngelo SP Pietanza MQ Johnson MLj | 2011 | J Clin Oncol2011，29，15： | 1 |
| 11 | Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker显示文摘 | Pietanza MC Kadota K Huberman K | 2012 | Clin Cancer Res2012，18，4： | 1 |
| 12 | The molecular pathogenesis of small cell lung cancer显示文摘 | Dngelo SP Pietanza MC | 2010 | Cancer Biol Ther2010，10，1： | 1 |
| 13 | Incidence of EGFR exon 19 deletion and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas 显示文摘 | D~Angelo SP Pietanza MC Johnson ML | 2011 | J ClinOncol2011，29，15： | 1 |
| 14 | The molecular pathogenesis ofsmall cell lung cancer显示文摘 | D'ANGELO S P PIETANZA M C | 2010 | Cancer Biol Ther2010，10，1： | 1 |
| 15 | In Reply to ‘Secondary Capillary Leak Syndrome Related to Pemetrexed Exposure’显示文摘 | Ilya G. Glezerman M. Catherine Pietanza | 2012 | American Journal of Kidney Diseases2012，，4： | 1 |
| 16 | A phase 2 study of the insulin‐like growth factor‐1 receptor inhibitor MK‐0646 in patients with metastatic, well‐differentiated neuroendocrine tumors显示文摘 | Diane L. Reidy‐Lagunes Efsevia Vakiani Michal F. Segal Ellen M. Hollywood Laura H. Tang David B. Solit M. Catherine Pietanza Marinela Capanu Leonard B. Saltz | 2012 | Cancer2012，，19： | 1 |
| 17 | Comparison of CT volumetric measurement with RECIST response in patients with lung cancer显示文摘 | Hayes SA Pietanza MC O' Driscoll D | 2016 | EUR J Radiol2016，85，3： | 1 |
| 18 | Phase Ⅱ study of temozolomide for relapsed sensitive or refractory small cell lung cancer显示文摘 | Pietanza MC Travis WD Chan TA | 2010 | Pancreas2010，39，2： | 1 |
| 19 | Incidence of EG-FR exon 19 deletions and L858R in tumor specimens from menand cigarette smokers with lung adenocarcinomas 显示文摘 | D Angelo SP Pietanza MC Johnson ML | 2011 | J Clin On-col2011，29，15： | 1 |
| 20 | Phase II trial of temozolo- mide in patients with relapsed sensitive or refractory small cell lung cancer,with assessment of methylguanine-DNA methyltransferase as a potential biomarker显示文摘 | Pietanza MC Kadota K Huberman K | 2012 | Clin Cancer Res2012，18，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员